Studies in the Area of Ocular Pharmacology and Therapeutics Reported from University of Iceland (Dorzolamide Cyclodextrin Nanoparticle Suspension Eye Drops and Trusopt in Rabbit)
By a News Reporter-Staff News Editor at Drug Week -- Current study results on Drugs and Therapies have been published. According to news reporting originating from Reykjavik, Iceland, by NewsRx correspondents, research stated, "Dorzolamide nanoparticle gamma-cyclodextrin eye drops may prolong the effect of dorzolamide on intraocular pressure. We test whether the nanoparticle drops have an irritating or toxic effect on the eye in an in vivo rabbit model."
Our news editors obtained a quote from the research from the University of Iceland, "Eighteen pigmented rabbits were divided into 4 groups receiving dorzolamide nanoparticle gamma-cyclodextrin eye drops 1/day or 2/day, Trusopt ® (dorzolamide HCl) x 3/day, and untreated controls that received no drops. The rabbits received treatment for 1 month. After sacrifice, 33 eyes and 25 Harderian glands were evaluated for histopathology in a masked way. Mild inflammation was seen in 19/31 eyes and 13/23 Harderian glands. The difference in inflammation (n = eyes/n = glands) between the gamma-cyclodextrin nanoparticle eye drops 1/day (n = 5/5), 2/day (n = 5/3), Trusopt (n = 7/4), or untreated control (n = 2/0) groups was nonsignificant in both eyes and glands (P = 0.87 and P = 0.92) Acute inflammation was seen in 1 Harderian gland that received gamma-cyclodextrin nanoparticle eye drops 2/day. The difference in conjunctival injection between the groups was nonsignificant (P = 0.30)."
According to the news editors, the research concluded: "Dorzolamide gamma-cyclodextrin nanoparticle eye drops are no more locally toxic or irritating to the eye than Trusopt."
For more information on this research see: Dorzolamide Cyclodextrin Nanoparticle Suspension Eye Drops and Trusopt in Rabbit. Journal of Ocular Pharmacology and Therapeutics, 2014;30(6):464-467. Journal of Ocular Pharmacology and Therapeutics can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - www.liebertpub.com; Journal of Ocular Pharmacology and Therapeutics - www.liebertpub.com/overview/journal-of-ocular-pharmacology-and-therapeutics/40/)
The news editors report that additional information may be obtained by contacting G. Johannesson, University of Iceland, Fac Med, Dept. of Public Hlth, IS-101 Reykjavik, Iceland. Additional authors for this research include M.D. Moya-Ortega, G.M. Asgrimsdottir, B.A. Agnarsson, S.H. Lund, T. Loftsson and E. Stefansson (see also Drugs and Therapies).
Keywords for this news article include: Europe, Iceland, Reykjavik, Drugs and Therapies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC